• PACR private placement comprised of 8,333,333 units for possible gross proceeds of $1.5 million
• Funding to support Company’s continued progress in current, potential efforts
• An example of Pac Roots projects includes JV with Rock Creek Farms, which resulted in profitable first harvest that delivered 200% ROI

Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) has announced a non-brokered private placement (https://ibn.fm/tYble) to strengthen its financial position as it focuses on the future of genetics and its commitment to quality over quantity. Headquartered in Canada, Pac Roots is dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach. The announcement of the private placement noted that up to 8,333,333 units would be offered at CDN$0.18 per unit for a potential of $1.5 million gross proceeds for the Company. Each unit consists of one common share in the capital of the PACR along with one common share purchase warrant, which will entitle the warrant holder the right to acquire an additional common share at CDN$0.30 for 36 months after the offering closing. The offering is expected to close on or about Feb. 12, 2021, subject to typical approvals. Pac Roots announced several significant initiatives in the past year, and the additional funding will support the Company’s continued progress and success in these projects as well as other operational expenses. Included in Pac Roots portfolio is a joint venture with Rock Creek Farms, which resulted in a profitable first project last fall that garnered an ROI of 200% (https://ibn.fm/AIN8Z). The completion of its successful 2020 outdoor premium CBD hemp harvest marks PacRoots’ first production project, and the impressive results are proof of how vital the combination of farming experience, suitable genetics, and an ideal climate and region are in producing a successful CBD hemp crop. The Company, which through a joint venture holds a Health Canada license to cultivate, sell, import, export, possess and process industrial hemp, announced that the yield for the 100-acre pilot outdoor hemp CBD harvest at Rock Creek Farms was “much higher than our expectations.” The total biomass harvest yielded more than 105,000 pounds. In the announcement of the harvest, Pac Roots noted that “with a very low cost to harvest, as opposed to greenhouse costs that currently dominate the industry, the Company has an opportunity to disrupt categories within the hemp industry. PacRoots believes that the largest advantage it has over its competition is its low-cost production, giving the Company the ability to be extremely price competitive on the market while continuing to maintain healthy profit margins.” “We are very proud of our team and partners at Rock Creek Farms who have been committed to the vision and dedicated to achieving success,” noted Pac Roots president and CEO Patrick Elliott. “In light of some unusual extreme weather, the team was able to react quickly and minimize crop loss from the early freezing temperatures experienced during the harvest. The JV is fortunate to have recovered as much tonnage as was realized under the circumstances that culminated at other farms in the Province. PacRoots and our partners are thrilled to build on this success as we launch into 2021 with various exciting projects.” For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• InsuraGuest expanded platform integration to 82 different property management systems and now connects with 90% of all property management systems used by the biggest names in hospitality
• InsuraGuest Hospitality Liability coverage can lower a facility’s claim ratio and risk profile, which may decrease the property’s general liability premiums, save money, time and aggravation for hotel and vacation rental operators
• InsuraGuest is pioneering a new standard, disrupting the insurance industry with its proprietary insurtech platform

InsuraGuest Technologies (TSX.V: ISGI) (OTCQB: ISGIF), a leader in the insurtech sector (insurance + technology), recently marked another major milestone in its mission to revolutionize the insurance industry. InsuraGuest is disrupting status quo insurance markets by leveraging its proprietary software platform to deliver digital insurance products that provide better benefits at lower costs across multiple industry sectors. One of the initial primary targets is the hospitality industry and recent news from InsuraGuest marks a new milestone in the company’s reach and scope of business in the hospitality sector. InsuraGuest recently announced it has expanded the reach of its insurtech platform to fully integrate with 82 different property management systems which are used by some of the biggest names in the hospitality industry. Utilizing InsuraGuest’s proprietary API enables hospitality properties to transfer some of their liability exposure from their facilities to InsuraGuest Hospitality Liability policies. Liability coverage for medical expenses, accidental property damage, stolen goods, or other mishaps usually has limitations and high deductibles. When these incidents are covered by a property’s general liability insurance it could cost a facility more than the actual event. InsuraGuest provides a layer of protection that responds to the property directly when guests experience mishaps. If accidents do happen, it’s quick and easy to file a claim. A large portion of a hotel, motel or Airbnb operator’s claims result from small property or medical claims. These are most often charged against the facility’s general liability policy and the frequency of these small claims drives up premium prices. By using InsuraGuest, the risk is transferred from the hotel or vacation rental operator by having guests pay a small fee per night. InsuraGuest collects the fees and then pays out these claims, bypassing claims against the general liability policy. This can lower a facility’s claim ratio and risk profile, which may decrease the property’s general liability premiums, saving money, time and aggravation for hotel and vacation rental operators. This is especially important to America’s small businesses looking for any edge to improve profitability. “Increasing our platform integration to 82 different property management systems gives us the ability to connect with over 90% of the systems in use today, systems which are used by Hilton, Marriott, Hyatt, Wyndham and Airbnb,” stated Douglas Anderson, chairman and CEO of InsuraGuest Technologies, Inc. InsuraGuest Technologies is focused on adding value to the insurance market and its customers by integrating insurance innovation and technology into a single flexible package. The company is guided by its motto, “Digital insurance reimagined, reinvented, revolutionized.” InsuraGuest is pioneering a new standard, disrupting the insurance industry with its proprietary insurtech platform, providing cost savings and an array of digital business insurance solutions with flexible pricing delivered in less than 60 seconds. The future of insurance has arrived. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Chinese mobile-based social and entertainment platform operator Momo is regrouping and revisiting its successes after suffering a pair of adverse conditions resulting from government concerns and pandemic problems
• Momo has developed a prominent reputation as “China’s Tinder” through its Tantan dating service platform and its Momo streaming video app
• The company saw some of its top leadership positions change last year in response to declines in revenue and stock value
• The company has generated some encouraging reports since the start of the year with a brief surge in stock value and forecasts that anticipate it will “retain growth momentum on both VAS and live broadcasting”

Chinese social media wonder Momo (NASDAQ: MOMO) is responding to a test of its mettle in the wake of adverse economic factors brought on by a brief battle with the country’s content regulators followed by the rise of the global COVID-19 pandemic. Momo owns the Tantan dating service known as “China’s Tinder” as well as its own-brand Momo live video streaming platform, two of the top dating and social interaction apps in China. Popular features include virtual gift-giving and blind date matching with other active users whose photo profile is blurred until after at least 20 messages have been exchanged. But the company saw significant declines in revenue and stock value during 2020 after the pandemic’s virus gained worldwide attention when it reportedly originated in a Chinese province and businesses there ground to standstill amid national efforts to stop the virus’ spread. Far from down for the count, Momo’s monthly active users (“MAUs”) numbered 113.6 million and net revenues stood at US$554.8 million as of last year’s third quarter financial report, the most recent for the company (https://ibn.fm/ePte4). The company monetized Tantan’s dating features, driving an increase in value added services (“VAS”) revenues by 27 percent YOY, according to the Q3 report. The company’s CEO stepped down in November to become the executive chairman of the board of directors and the chief strategy officer stepped down in December for personal reasons but will continue to serve as a senior advisor to the Company, according to the report. In January, Momo’s shares enjoyed a brief surge after well-known options trader Jon Najarian talked about “unusual activity” in call options and mentioned his Momo options in furtherance of the discussion on CNBC’s Fast Money program (https://ibn.fm/lRutu), and the company continues working to achieve a sustainable rebound. “The third quarter of 2020 was a busy quarter for us. As a result of management’s commitment and the persistence of our colleagues, the structural reform within the core live broadcasting business has achieved initial success,” new CEO Li Wang stated in the Q3 report. “Although we have more hard work to do down the path, what we have achieved so far gives us the confidence that our live streaming business has entered into a virtuous cycle supported by a sustainable content ecosystem.” Despite the challenges, Deutsche Bank analyst Leo Chiang told Yahoo! Finance that Tantan’s average revenue per user (“ARPU”) has been “growing sharply sequentially” and that he expects Tantan to “retain growth momentum on both VAS and live broadcasting but in a moderate manner.” Chiang foresees a gradual turnaround in the second half of the year (https://ibn.fm/lsVU0). For more information on Momo Inc., visit the company’s Investor Relations web page at https://momoinc.gcs-web.com.

• FDA has authorized 225-plus diagnostic tests for COVID-19 since pandemic began
• CareStart(TM) COVID-19 antigen test received FDA authorization in July 2020
• UME carries CareStart antigen kit, a powerful component of COVID-19 screening process

Since the beginning of the COVID-19 pandemic, the U.S. Food and Drug Administration (“FDA”) has authorized more than 225 diagnostic tests for COVID-19 in an effort to provide growing resources to combat the disease. United Medical Equipment Business Solutions Network (“UME”), a company committed to offering a comprehensive line set of COVID-19 products, recently added one of those tests — the CareStart(TM) COVID-19 rapid antigen kit — to its product line.

“The FDA strongly supports innovation in test development and we have worked tirelessly with test developers to support the shared goal of getting more accurate and reliable tests to Americans who need them,” said Jeff Shuren, MD., J.D. and director of the FDA’s Center for Devices and Radiological Health (https://ibn.fm/rVMjI).

The CareStart COVID-19 antigen test received FDA authorization in July 2020 (https://ibn.fm/iFrI8). In a letter to Access Bio Inc., the company that manufactures the test, FDA chief scientist Denise M. Hinton explained that the secretary of the Department of Health and Human Services (“HHS”) had “determined a public health emergency existed that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19.”

Hinton noted that the circumstances justify the authorization of diagnostic measures designed to detect or diagnose the virus that causes COVID-19, and therefore, “I am authorizing the emergency use of your product,” Hinton wrote.

The CareStart COVID-19 Antigen packaging material notes that “due to the highly contagious nature and global spread, SARS-CoV-2 . . . continues to have devastating impacts on healthcare systems and the world economy, including the U.S.” (https://ibn.fm/OSKkr). Systematic screening and detection of both clinical and asymptomatic systems is an essential piece of ending the SARS-CoV02 pandemic, and the CareStart antigen kit can be a key component of that screening process. The innovative test features a 10-minute processing time, identifies acute infection with 88.4% sensitivity and 100% specificity, and helps provide critical answers about active infections to patients and healthcare workers alike.

The CareStart product is part of UME’s comprehensive COVID-19 monitoring strategy, which was carefully designed with the assistance of medical experts and includes ongoing, data-driven COVID-19 testing. In addition to the CareStart COVID-19 Antigen tests, UME provides a wide array of other COVID-19 supplies and products, including sanitizers, gloves and face shields, thermometers, hoods and masks.

UMEs’ mission is to provide guidance for caregivers, veterans, the aging population and the medical community through its robust medication management and telehealth applications. In addition, the company recognizes the importance of being socially responsible as a corporation by giving back to the world through emergency assistance grants awarded to seniors, with an emphasis on veterans, by supporting nonprofits in their missions, and by supporting the American economy by providing work-at-home opportunities.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• Recent article finds that data remains one of main drivers of medical research in 2021.
• New technologies employing AI powered by big data provide new solutions for tackling health problems, expand possibilities of clinical research
• RYAH combines power of devices combined with data to impact future of medical research to advance treatment of various medical conditions

A recent Becker’s Hospital Review article cites 10 emerging trends in health IT that will shape this field in 2021, reporting that big data management is becoming a need as the use of artificial intelligence (“AI”) and machine learning in healthcare continues to blossom (https://ibn.fm/bMPIY). With the increasing demand in the medical space for application of analytics powered by novel technology, RYAH Group is set to benefit as a leading digital health care analytics and technology company committed to advancing the world’s transition to remote-health solutions and data analytics in patient treatments. With the digitalization of medical records and improved medical analytics coupled with a proliferation of wearables, there has been an explosion of medical data over the past decade. That explosion has led to a revolution in medical and health-care research. The vast amount of data available for analysis enables AI-powered algorithms to transform the medical field more than ever before, helping to define what is healthy and to diagnose, treat and prevent any deviations from the ideal standard. The applications go beyond the individual level, offering solutions to tackle health challenges at the level of humanity. Blossoming of artificial intelligence and machine learning in health care, driven by a combination of wearables and other biomedical devices, will continue to transform clinical research and treatment protocols as well as increase the virtual-care capabilities of health providers, the article observes. “AI is not new in healthcare,” the article notes. “But in the last year AI became crucial in developing predictive models for COVID-19 cases spreading across the country. . . . The field will continue to evolve and become more integrated with clinical care in the coming years.” Technological advancements make these developments possible as the data continue to be the major trend shaping medical research. The article reports that big data management becomes mission critical as the pandemic highlighted the need for centralized and efficient data management. The data-gathering and reporting efforts accelerated during the virus outbreak, propelling organizations of all sizes to consider cloud implementations to securely store and coordinate data as secure medical research becomes a priority. As a company committed to leveraging the value of health devices combined with data to positively impact the future treatment of patients with various medical conditions, RYAH is set to be at the forefront of the data-driven medical future. Indispensable in modern medical research, data is at the core of the company’s strategic approach. RYAH aggregates data collected by its product ecosystem, creating a HIPAA-compliant database enhanced by AI-powered solutions designed to analyze and clarify complex relationships between peer-reviewed research, consumer feedback and therapeutic plants. As the company specializing in unlocking data in the complete therapeutic plant lifecycle – from seed to consumption – RYAH appears strategically placed in the $100.3 billion medical plant market, with the potential to capitalize on growth opportunities enabled by both the IoT and data intelligence (https://ibn.fm/wKPTg). For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• Investor uncertainty rising as volatility continues to negatively affect stock market
• SRAX’s Sequire investor analytics platform provides actionable insights into investor behaviors for public companies
• Sequire has grown to 3 million+ active users across 90 public companies since 2019
• Q3 2020 performance includes $6.7 million in bookings, 37% increase in subscriptions, 161% year-over-year and 124% quarter-over-quarter revenue growth

Despite record levels of unemployment, threats of extreme inflation and runaway government spending, the stock market appears to have decoupled from the greater economy with record highs amid unprecedented levels of volatility (https://ibn.fm/fEiHi). As uncertainty among investors continues to grow, many public companies are choosing clarity over confusion through the use of Sequire, SRAX Inc.’s (NASDAQ: SRAX) SaaS platform that helps its users unlock the power of investor data so they can activate marketing campaigns that engage both current and prospective investors.

There’s never been a greater need for actionable, reliable investor data than in recent weeks. Market volatility has reached unparalleled levels, credited mostly to irrational trading, investor reactions to new government policies, derivatives speculation and anticipated earnings reports. “There’s a lot of news to digest for investors,” said J.J. Kinahan, chief market strategist at TD Ameritrade. “We’ve had such an incredible run, and 20% of the S&P 500 are releasing earnings this week.”

Sequire is the answer for many public companies looking to harness the power of big data for reliable analytics derived from the platform’s 3 million+ active users, a group which includes investors and traders from over 90 public companies (https://ibn.fm/0D6lL). The platform’s unique set of tools help users obtain insights through investor intelligence and outreach, warrant tracking, survey creation, event promotion and roadshows.

“The platform is an absolute game-changer for public companies and their shareholders,” said LD Micro founder Chris Lahiji in statements about the recent acquisition of the company by SRAX. “Both companies believe that one day executives will rely on Sequire the same way investors rely on Bloomberg.”

Sequire’s sales performance in 2020 was outstanding with over $6.7 million in bookings in Q3, its first positive quarter EBITDA. Along with a 37% increase in subscriptions, the platform experienced impressive 161% year-over-year and 124% quarter-over-quarter revenue growth.

“Sequire is changing the way public issuers interact with and engage their investors, and it shows,” said SRAX CEO and Founder Christopher Miglino (https://ibn.fm/I5gHA). “We are pleased to report our first quarter of positive EBITDA from our Sequire segment.”

Besides Sequire, SRAX is also focused on building the largest and most reliable opted-in data sets across a broad range of industry verticals. The Company is dedicated to providing brands and companies across the CPG, luxury, and lifestyle spaces with high-quality data that provides key, actionable insights integral to strategic marketing campaigns.

SRAX is a financial technology company that helps public companies unlock the power of data through Sequire, its premier investor intelligence and communications platform. Sequire helps companies track investor behaviors and identify trends for use in campaigns to engage current and potential investors across multiple marketing channels.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Excellon’s portfolio currently includes active production at the Platosa Mine, with four additional assets in the development or exploration stages
• Excellon saw significant increases in production of lead, zinc and silver at the Platosa Mine from Q4 2019 to Q4 2020
• The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration
• The Company implements a practical management system that addresses the safety, health, security, environmental and community aspects of mining, as per the UN Sustainable Development Goals
• Excellon employs a world-class leadership team with a proven track record of successfully managing and developing similar mineral projects across the globe
• The global market size for precious metals was valued at $193.3 billion in 2020 and is expected to grow to $362.1 billion by 2027

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://ibn.fm/Wdnco). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027. Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5%.

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

• Silver – 355,581 oz – $24.46
• Lead – 2,223,465 lbs. – $0.87
• Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://ibn.fm/l2mfr).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://ibn.fm/UKkSY). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

For more information, visit the company’s website at www.ExcellonResources.com.

NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN

• XPhyto Therapeutics Corp. is a life sciences technology accelerator involved in the development of new pharmaceuticals, diagnostic products and psychedelic investments
• XPhyto is preparing a series of clinical pilot studies for four drug candidates this year that could help in treating Parkinson’s disease, epilepsy, anorexia and other neurological conditions
• The company has developed a rapid and highly portable PCR test kit it expects to commercialize this year to provide point-of-care diagnostics, designed for satellite labs to quickly screen for the COVID-19 virus
• Wholly owned subsidiary Vektor, a German drug maker and researcher, plans to build a new commercial drug manufacturing facility this year to help advance XPhyto’s vertical integration plans

Bioscience industry holding company XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is accelerating its mission to advance next-generation drug delivery, diagnostic products and new active pharmaceutical ingredient investment opportunities following a series of successes in 2020 that kept the company productive despite global pandemic conditions.

The goals for the coming year include wholly owned subsidiary Vektor’s construction of a new commercial drug manufacturing facility in Germany, clinical pilot studies for four drug formulation programs XPhyto built up during 2020, taking its COVID-19 PCR test and at least one of its novel, in-house-manufactured biosensor products to market, and the introduction of various psychedelic compounds into Vektor’s drug formulation platforms for the potential treatment of mental health conditions such as depression, anxiety, addiction and trauma-related stress disorder (https://ibn.fm/JgzXk).

“2021 is expected to be a transformative year for Vektor. We will be building on significant momentum from 2020 as we advance our drug formulation, contract development, and psychedelic business,” Prof. Dr. Thomas Beckert, managing director of Vektor Pharma TF GmbH, stated as part of the company’s announcement. “The addition of scalable in-house manufacturing capability creates the potential for significant growth across virtually all of our development and commercialization programs.”

XPhyto was founded in 2017 and in 2019 began listing its common shares on the Canadian Securities Exchange, continuing to extend its reach internationally since then. The company’s lead diagnostic product is a rapid and highly portable PCR diagnostic test expected to play a significant role in COVID-19 testing for economically devastated travel industries, as well as other sectors. XPhyto anticipates European commercial (CE-IVD) approval in the first quarter of this year.

Vektor is a German narcotics developer and researcher that has been a leader in the design, testing and manufacture of thin film drug formulations such as skin patches and under-the-tongue strips that deliver active pharmaceutical ingredients (“API”) for over a decade. Its products primarily target pain and other neurological conditions.

XPhyto’s planned drug pilot studies include a Q1 program for Rotigotine, a transdermal patch for Parkinson’s disease patients; a sublingual cannabidiol (“CBD”) strip for epilepsy patients in Q2; a Q3 program for a sublingual tetrahydrocannabinol (“THC”) strip for anorexia and nausea sufferers and an oral CBD / THC strip for people with spasticity difficulties as a result of Multiple Sclerosis.

The “open label, randomized, crossover, two-period, two-sequence, single dose” studies will assess the relative bioavailability of each product and will lead to a final pivotal study and application for regulatory approval if the results are successful.

Potential commercialization and licensing agreements being discussed may lead to enhanced monetization opportunities for the company.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• Precision medicine in oncology allows for clinicians to develop personalized cancer treatment plans using individual characteristics of each patient
• Doctors use insights drawn from laboratory-grown cancer cells, patients’ DNA to individualize cancer treatment
• Predictive Oncology has been forerunner in its field, both through Helomics division’s smart tumor profiling platform as well as TumorGenesis subsidiary, which creates the tools used in ovarian cancer research
• TumorGenesis has begun to commercialize intellectual property, having received first order for unique ovarian cancer cell culture media in June 2020

In the summer of 2018, 49-year-old Star Dolbier arrived at the University of Maryland Greenebaum Cancer Center with a large mass on her left lung; at the time, the five-year survival rate for her type of advanced lunch cancer was only six percent (https://ibn.fm/iVEw5). However, tests carried out on tiny fragments of tumor DNA allowed her to be treated with a novel drug treatment, virtually eradicating the cancer from her system only 18 months later. In addition to looking at mutations in tumor DNA, oncologists have increasingly begun using laboratory-grown tumors or cancer cells to test the effectiveness of different cancer drugs, thereby helping determine the best course of treatment for a specific individual. Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment through its Helomics division.

Predictive Oncology is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

The use of precision medicine in oncology – a field wherein doctors use insights drawn from laboratory-grown cancer cells and their patients’ DNA to prescribe personalized drug treatments, has seen exponential growth in recent years. Rather than resorting to a one-size-fits-all standard of care, oncologists can prescribe more personalized medicines, with last year seeing the approval of over two dozen such drugs (https://ibn.fm/76SNE); over the next two years, forecasts predict that the number of new personalized treatments will outnumber those developed for the general population.

POAI’s wholly owned TumorGenesis subsidiary specializes in the field of ovarian cancer, developing tools (kits, reagents and specialty cell-culture media) to grow tumors and cancer cells in a manner that mimics the patient’s own body.  TumorGenesis’ proprietary Oncology Capture Technology Platform isolates and cultures the patient’s heterogenous tumor sample, providing a much better model of the tumor outside the body (ex vivo). These improved ex-vivo tumor models can then be used by researchers to investigate cancer and by clinicians to develop patient-specific treatment plans (https://ibn.fm/xhryO). TumorGenesis announced that the division had sold its first order of its unique ovarian cancer cell culture media to a New England-based university seeking to carry out research utilizing laboratory-grown cancer cells.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Hollywall Entertainment Inc. is a technology and broadcasting company with a deep reserve of entertainment media content that it is distributing through its network in the U.S. East and South regions
• Hollywall began rolling out its new, wholly owned brand HW Vision at the end of January to provide cellular equipment and services, streaming media content, live television and on-demand programming
• HWAL’s mission is to use its growing telecommunications prowess as a socio-economic equalizer for rural and underserved minority communities
• The company’s telecommunications networks will also deliver capabilities for telemedicine and tele-education — services that have become valuable during the ongoing global pandemic that has led to limitations on in-person gatherings

Telecommunication and broadcasting company Hollywall Entertainment (OTC: HWAL) has begun rolling out its new wholly owned subsidiary HW Vision to provide branded cellular equipment and services, streaming media content, live television and on-demand programming as part of Hollywall’s drive to become a major media and entertainment conglomerate. HWAL’s subsidiary HW Vision is advancing its newly acquired company Omnipoint Technology, Inc., a Massachusetts-based telecommunications company, to deliver the services — including content from Hollywall’s large entertainment library and educational programming catalogue — to residential homes and commercial businesses through its network across the Eastern and Southern United States, according to a recent company announcement (https://ibn.fm/s8kAB). HWAL’s growth is fueled by a dedicated mission to level socio-economic playing fields through telecommunication services to underserved communities and minority populations. The company’s mission supports the growth of U.S. minority business enterprises (“MBEs”) owned and operated by African Americans, Asian Americans, Hispanic Americans, Native Americans, and Pacific Islanders and their communities. “We will faithfully remain steadfast and committed to our work to deliver on our promised mission of Fiber to the People (TM), inviting a beacon light of hope to inspire those that live within the fringes of some (of) our nation’s most devalued and disenfranchised communities, who continue to endure the suffrages from the lack of internet access symbiotic of the ever-widening digital divide,” Hollywall President and CEO Darnell Sutton stated in the company announcement. “We as a nation of all races, color, and creed must come together in unity and take a firm stand against all racial and social injustices, or sadly, we will remain enthralled within the midst of one of the greatest challenges of a spiraling disparity that will no doubt eventually adversely affect an entire new generation.” Another HWAL subsidiary, Hollywall Development Company (“HWDC”), specializes in the design, creation and management of 5G fiber networks. Its initiatives and investments include broadband and 5G networks, Internet-dependent products and services (“IOT”), smart city technologies, telemedicine, tele-education and waste management. Telemedicine and tele-education have been particularly useful services during the past year as the global COVID-19 pandemic has led to a variety of “distancing” standards designed to reduce the spread of viral infection but that have also prevented schools, businesses and health clinics from operating in the freely accessible, in-person reception manner that has historically served as the nuts and bolts model for commerce. The company also continues to expand its U.S. Governmental Affairs and Lobby Division portfolio as part of the effort to develop broadband networks nationwide with the help of national public works companies and federal agency partners. For more information, visit the company’s website at www.Hollywall.com. NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL